Subscribe To
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccin...
April 16, 2023, 5:00 pm
Moderna cancer vaccine with merck’s keytruda delays return of deadly skin cancer
By Julie Steenhuysen and Michael Erman (Reuters) – An experimental mRNA vaccine developed by Moderna ...
April 16, 2023, 3:19 pm
Moderna shows progress toward cancer vaccines
An mRNA shot helped prevent relapse in high-risk melanoma patients....
April 16, 2023, 11:00 am
Is it too late to buy pfizer stock?
Pfizer shares climbed in the double-digits through the earlier stages of the pandemic as vaccine sales ...
April 14, 2023, 5:30 am
Commercial aquaculture vaccines market is projected to reach a revenue of us$ 605.5 million by 2033 | persistence market research
Growing Investments in Novel Biologics will propel the overall Market for Commercial Aquaculture Vaccin...
April 13, 2023, 4:25 pm
Moderna (mrna) posts 2027 biz view, down 3% on flu jab setback
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its fir...
April 12, 2023, 12:55 pm
Novavax outlook: why nvax stock could 12x in the next 12 months
After recently reporting strong clinical data, Novavax (NASDAQ: NVAX ) has tremendous opportunities in front of it. More specifically, the company's...
April 12, 2023, 12:35 pm
Moderna stock drops on mixed data tied to flu vaccine approval
The Yahoo Finance Live team discusses the three stocks to watch, including Moderna, whose stock fell after a release of contrary data related to their...
April 11, 2023, 4:20 pm
Google drops global vaccine requirement to enter buildings, says 'world is in a very different place'
"The world is in a very different place," a Google global security vice president said in a companywide memo....
April 11, 2023, 3:57 pm